
CareDx, Inc
- Jurisdiction
United States - LEI
549300NQOFKL9NON0U06 - ISIN
US14167L1035 (CDNA )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€13.87 10.2% undervalued - Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. Read full profile
Fundamentals
- Net revenue
€290.71M - Gross margin
66.7% - EBIT
€34.16M - EBIT margin
11.8% - Net income
€44.08M - Net margin
15.2%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
N/A |
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Novack Jeffrey Adam | Secretary and General Counsel |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Cathie Wood |
|
|
|
Sell |
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)